SARS‐CoV‐2 infection correlates with male benign prostatic hyperplasia deterioration

Abstract

AbstractIntroductionSevere acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) affects extra‐respiratory systems, with small‐scale studies showing worsened male lower urinary tract symptoms (LUTS) after coronavirus disease 2019 (COVID‐19). This study explores the correlation between SARS‐CoV‐2 infection and male benign prostatic hyperplasia (BPH) complications using large‐scale real world data.Materials and methodsAll male patients attending the public healthcare system in Hong Kong receiving alpha‐blocker monotherapy for LUTS from 2021 to 2022 were included in this study. Patients with and without positive polymerase chain reaction (PCR) test for SARS‐CoV‐2 are selected as the exposure group and control group, respectively. Baseline characteristics are retrieved, with propensity score matching performed to ensure balance of covariates between the two groups. BPH complications were then compared and subgroup analyses were performed.ResultsAfter propensity score matching, 17,986 patients were included for analysis, among which half had PCR‐confirmed SARS‐CoV‐2 infection (n = 8993). When compared to controls, the SARS‐CoV‐2 group demonstrated statistically significant higher incidence of retention of urine (4.55% vs. 0.86%, p < 0.001), haematuria (1.36% vs. 0.41%, p < 0.001), clinical urinary tract infection (UTI) (4.31% vs. 1.49%, p < 0.001), culture‐proven bacteriuria (9.02% vs. 1.97%, p < 0.001) and addition of 5ARI (0.50% vs. 0.02%, p < 0.001). Subgroup analysis demonstrated similar differences across different age groups. There are no statistically significance differences in incidence of retention, haematuria, or addition of 5ARI across different COVID‐19 severities.ConclusionsSARS‐CoV‐2 infection is associated with increased incidence of urinary retention, haematuria, UTI and the addition of combination therapy in the short term, regardless of COVID‐19 severity. This is the largest study demonstrating the detrimental urological effects of SARS‐CoV‐2 infection.